 control trial foscarnet vidarabin acyclovir-resist mucocutan herp acquir immunodefici syndrom aid clinic trial group background and method strain herp simplex viru resist acyclovir suscept vitro foscarnet vidarabin random trial foscarnet vidarabin patient acquir immunodefici syndrom aid mucocutan herpet lesion unrespons intraven therapi acyclovir minimum day patient foscarnet mg kilogram bodi hour vidarabin mg day day isol herp simplex viru vitro resist suscept result lesion patient day therapi contrast vidarabin failur patient time heal time percent reduct size lesion pain score time end viral patient patient new neurolog abnorm vidarabin patient foscarnet toxic initi recurr herp simplex infect index lesion suscept acyclovir-resist infect heal patient median day rang foscarnet conclus treatment acyclovir-resist herp simplex infect patient aid foscarnet efficaci frequent seriou toxic vidarabin treatment high frequenc relaps